Welcome to Our stocktraders-icq.com© Website.
WARNING - After-hours investing involves unique risks. These risks may include greater price volatility, less liquidity, and wider bid/ask spreads than during regular market hours.
The Week Past
Well, we had the Dow down last week by finishing -0.2% for the week, the Nasdaq finished the week +0.3%, The S & P 500 was +0.9%, and the Russell 2000 was -1.3%. All traders should pay closer attention to their mental stops or plan on riding out some bumps along the way.
This last week was a small downturn for the Dow and a small upturn for the Nasdaq. We believe margin is fine to use if you DO NOT margin all your holdings. We feel it would be prudent to have 1/2 of an account on margin at this time.
We believe that a long-term or swing-trader should have 1/2 of their portfolio on margin at this time. A daytrader could have some margin of up to 3/4 of his holdings if you use tight stops. We want short-term traders to have their stops in at -5%. We suggest using -20% stops on your long-term positions at this time.
Well, the Dow was down medium and the Nasdaq finished the week down medium.
Last Weeks Economic News
The Economic reports coming this week are: on June 19th at 8:30 Am EST the Housing Starts and Building Permits reports will be released and on June 21st at 8:30 AM EST the Initial Claims for state joblessness benefits report will be released and at 8:30 AM EST the International Trade report will be released.
This Weeks Economic News
The reports are: on June 25th at 10:00 AM EST the Existing Home Sales report will be released; on June 26th at 8:30 AM EST the Durable Goods Orders report will be released, at 10:00 AM EST the Conference Board Consumer Confidence report will be released, and at 10:00 AM EST the New Homes Sales report will be released; on June 27th at 2:15 PM EST The Fed will release their report on interest rates and if there will be a interest rate cut; on June 28th at 8:30 AM EST the Initial Claims report for state joblessness report will be released; and on June 29th at 8:30 AM EST the Gross Domestic Product (GDP) report will be released and at 10:00 AM EST The Philadelphia Fed Index and Chicago PMI reports will be released. These reports will rate a C to A+ on a scale of A-F. Everyone should place close attention to pre-market trading and how the futures are acting each morning before the market opens for trading.
IPOs by M_A_Trader©:
Ipos are not coming out now as the market goes lower. There will not be many ipos coming to the market so check them out on at this web site. Click on Ipo Info is a great site to research ipos.WARNING: IF YOU BUY IPOs AFTER THE STOCK OPENS USE LIMIT ORDERS ONLY.
We have heard FRONTIER OIL CORPORATION (NYSE: FTO) may become a takeover candidate at $15-16. This stock would be a very speculative play in the energy sector. Buy under $9 with a mental stop at $6 ½. Well, FTO is at $12.45 on May 15th so we would recommend a trader sell ¼ of their holdings and take some profits off the table if they bought below $9. Hold the rest for our $16 target and move the stop up to $11.75. Only use money you can afford to lose all of it in this type of trade.
FTO hit our stop of $11.75 on May 23, 2001 so if you still hold some FTO you should have been stopped out at a nice gain.
FTO hits $17.00 for a high on June 6, 2001 so it did our target of $16.00.
The FED cut rates 50 basis points on May 15, 2001. The Fed will next meet on June 26-27, 2001. The FED funds futures suggest a 25 basis point rate cut at this time. The economy is giving mixed signals some signs point to strength and some signs point to weakness.
"A" Portfolio Stock Report by M_A_Trader©
We added more MDT at $41.25 and AAPL at $23.25 to the "A" Portfolio on May 23rd, 2001.
AAPL ($23.99) News for AAPL: No new news for AAPL. AAPL
We added MDT at $43.86; ISIL at $29.75; RETK at $29.75; and CTLM at $30.75 to our "A" Portfolio.
Here is some information on the above four stocks.
MDT ($47.10): Medtronic, Inc. News for MDT: No new news for MDT. MDT
CTLM: Centillium Communications. News for CTLM ($22.20): No new news for CTLM CTLM
ISIL ($30.20): ISIL News for ISIL: "RVINE, Calif.--(BUSINESS WIRE)--June 21, 2001--Intersil (Nasdaq:ISIL), a leading provider of power management solutions for PCs, file servers and portable information appliances, announced today the release of two new Endura(TM) pulse-width modulation (PWM) linear power system controllers. The devices provide power control and protection for DC/DC converters that are specifically designed and optimized to regulate power to the central processing unit (CPU) in Intel(R) Pentium(R) III-based, voltage regulation module (VRM) 8.5-compliant desktop PCs. These circuits are the first to integrate power sequencing functions required by VRM 8.5, thus reducing converter bill-of-materials (BOM) cost compared to competing solutions requiring extensive external components to perform this function. Intersil's Endura ISL6523 is a dual PWM and dual linear controller and the ISL6524 is a single PWM, triple linear controller. Both highly integrated devices provide power control and protection for four output voltages in VRM 8.5-compliant, high-performance microprocessor and computer applications. VRM 8.5 is an Intel specification for the latest Pentium III processors. The specification governs the regulation of power delivered to the processor. "These innovative latest additions to the Endura power management family leverage our design expertise to expand our leadership in the DC/DC power conversion market," said Rick Furtney, vice president and general manager of Intersil's Power Management product line. "As power requirements for PCs and information appliances grow in complexity, systems designers are required to carefully consider voltage requirements and power efficiency. Intersil continues to lead the industry by delivering highly efficient power management products that meet the challenges defined by today's advanced computing devices." ISIL
RETK ($38.60): etek Inc. News for RETK: "MINNEAPOLIS, June 25 /PRNewswire/ -- Retek Inc. (Nasdaq: RETK), the leading provider of solutions that help the retail industry create, manage and fulfill consumer demand, has enjoyed explosive customer success during the first six months of 2001, despite a tight economic retail market. "Retailers know that Retek helps optimize current processes, creating an information infrastructure to support business goals, such as decreasing returns and perfecting replenishment," said Retek Chairman and CEO, John Buchanan. "During slow economic times, increasing production and speed-to-market often work against retailers, but optimizing the retail experience to ensure that customers receive the right products at the right time and right price allows retailers to cut costs by optimizing production, not increasing it." Grocery Customers Optimize Supply Chain to Maintain Margins Retek is working with top grocers in the U.S. and U.K. to help optimize grocery supply chain processes. With tight margins, grocers must run at peak performance or risk losing millions with wasted product. Both The Kroger Company, the largest U.S. grocery chain, J. Sainsbury PLC, Britain's longest standing grocery chain, are working with Retek to lower operating costs through improved inventory management. "As a 25 billion retailer with more than 440 stores in the U.K., it is essential that we have high data integrity throughout our organization," said Martin Webb, Sainsbury. "This new solution provides a scalable foundation that will drive improvements in our planning, forecasting and replenishment activities. Retek has proven to be the leader in retail solutions, particularly in the unique environment of the grocery marketplace. Partnering with Retek is one of the first steps to upgrade our systems, and we expect to yield major benefits over the coming years." Retailers Rally Around Retek Logistics & Merchandising Fashion and other non-food retailers must make the most of the customer shopping experience by offering a custom experience based on consumer demand. Tony Hyett, director of supply chain management, Wilsons Leather says, "In the fashion business managing lead times to get the right product to the right location at the right time, as efficiently as possible, is extremely important. We performed an extensive evaluation of the leading solutions in the market and selected Retek. Retek's functionality and capability to extend beyond the four walls of the distribution center, providing merchandise visibility and control throughout Wilson's supply chain, are key differentiators." Other notable retailers who have either selected or gone live with Retek logistics and merchandising solutions during the first six months of 2001 include Gap, Barnes & Noble, Clarks, Jungle.com, WHSmith, Selfridges and Tesco. Retek Poised for Retail CRM Growth According to a recent report by industry research firm Gartner Group(1), the retail industry is in the early stages of CRM adoption as a key business strategy. The vast majority of retailers are assessing the feasibility of these solutions and evaluating products and vendors. Retek is the only retail solutions company with a retail-specific CRM solution designed to integrate with other business systems, allowing retailers to work with the systems they have in place, integrating critical customer information with CRM systems. Retek's current Retail CRM customers include world-class companies such as Tosco and Jungle.com. Retek expects to announce new wins in this solution group in the coming weeks." RETK
We have added AXP at $37.50; FRE at $60.50; and XLF at $25.50 to the "A" Portfolio a few weeks ago. All three stocks are in the financial sector. Here is some information on all three companies.
AXP American Express ($39.88). News for AXP: No new news for AXP. AXP
FRE ($68.70) News for FRE: No new news for FRE. FRE
Financial Sel Sect Spdr Fd (AMEX: XLF $28.57) is a sector spider traded on the AMEX.
The upper resistance levels for the Nasdaq is 2,150 and then 2,375. Support is at 2,000 and then 1,850. We would like to see the Nasdaq stay above 2,000. The Dow has support at 10,500 and then 10,300. Resistance is at 11,300. The Dow is going under 10,600 support so we would like the Dow to stay above 10,300.
We have been using this as a guideline only. We are holding some stocks with a loss of over -30%. If this market breaks down lower we may dump some of the losing stocks that are in our "A" Portfolio. The "A" Portfolio is going to a strict percentage gain or loss sell mode for now with the market fluctuating so much at this time. If a position moves up +20% one-quarter of the position will be sold, at +40% another one-quarter will be sold, and then at +75 to +100% another one-quarter of the position will be sold. That will leave one-quarter of the position to ride the stock higher. We still will use -30% to exit a stock position. Our targets for these stocks are on our Charts page.
We will talk about more of the stocks in the "A" Portfolio in the coming weeks.
All the past additions to the "A" Portfolio are on this page now."A" Portfolio Additions
Please read our disclaimer about the "A" Portfolio here. "A" Portfolio Disclaimer
Stock Charts for 2000 and 2001
The Charts page will be up and running by the end of June 2001.This page has links to all our stock charts and "A" Portfolio results for 2001.The Charts
After we turn from overall market downward momentum to upward momentum these two Canadian companies should rebound well.
Infowave Wireless (IW:TORONTO) Target US$30 Infowave is well positioned to take advantage of the coming boom in wireless email. Thomas Koll(a current VP at Microsoft) will be starting as the companies CEO on February 15. They have many impressive partners including Intel, Nokia and Compaq. Current market conditions have made this stock very oversold.
Rogers Communications (RCB.A:TORONTO) Target US$42 Rogers is Canada's largest cable television company they also have their hands into providing high speed internet as well as cellular and paging services. The long-term outlook for this company is stable and is likely to see steady growth in a booming industry.
Stocks We Like
Research in Motion closed the week at $28.28 we have lowered our 12 month target to $155 (RIM, TSE) (RIMM, NASDAQ). We are letting RIMM run for our target of $155. Since we already have PALM a trader may want to add HAND and have all three in their portfolio.We added RIMM at $40 ¼ and today March 28th we added more RIMM at $20.You may have to hold RIMM for 12 - 18 months depending on how the market is doing. RIMM has found partners in AOL and Compaq. Amazon has Crackberry available for $499 with service available at $39.95 per month. News for RIMM: No new news for RIMM. RIMM
VIRS (4.02 ) is a very speculative buy at this time. VIRS is a strong buy if it sinks down to $4 1/2 - 5 1/2 Only buy it if you can afford to lose all you invest in it. The chart for VIRS is looking good so continue to hold this stock for our $35 target. News from VIRS: No new news for VIRS now.
Management and product development strategy is available on Triangle's website at: VIRS
We are adding another blown up stock as a speculative buy. We are adding ZOOX (3.15), as a very risky buy at $2 ½ or lower with a target of $29 in 24 months. ZOOX is currently having a slow down in sales year to year. Its new switch for SANS are not selling as well as management expected. New management has been installed but it may take two or more quarters to fix their inventory oversupply. Well, ZOOX has not been doing very good since we recommended it a few months ago. We would average into more of ZOOX and hold for the long-term. ZOOX may be dead money for the next two-three quarters. News for ZOOX this week: No new news for ZOOX. Only buy this stock if you can afford to lose your entire investment in ZOOX.ZOOX
We are looking at adding IOM Iomega Corp. ($2.14) to our "A" Portfolio under $3.00. It has come out with a new storage device for home computers that will hold 10-20 Gigs of data. IOM is another beaten up high tech stock so only invest money in it you can afford to lose all. We added more IOM at $2.10 to our "A" Portfolio on June 18, 2001.
Iomega Corporation designs, manufactures and markets innovative storage solutions, based on removable-media technology for personal computer & electronics device users. IOM
News for IOM: "ROY, Utah, June 25 /PRNewswire/ -- Iomega Corporation (NYSE: IOM), a global leader in reliable portable data storage, will unveil the new Zip(R) 100MB USB Powered drive this week at PC Expo. The stylish Zip 100MB USB Powered drive is roughly half the size of its predecessor and receives both data and power through a single USB cable. By eliminating the need for a separate power cord, Iomega has made its industry standard Zip drive more portable and easy to use than ever. Included with the drive is Iomega QuikSync(TM) automatic backup software, a 39.95 value. With QuikSync software, files saved to any protected directory are transparently copied to the Zip 100MB USB Powered drive. Users can also choose between continuous backup or customized scheduling. "Digital solutions should make life simpler," said Doug Collier, senior vice president, marketing and product management, Iomega Corporation. "Getting the full functionality people expect from a Zip drive is as simple as plugging in one cable, and our QuikSync software is the simple tool that computer users need to keep their important data backed up and safe from viruses, computer crashes and other threats." In addition to QuikSync software, the new Zip 100MB USB Powered drive includes software for easily copying an entire floppy collection to a single Zip disk, managing digital audio files, editing digital photos, and accomplishing other tasks. The new Zip 100MB USB Powered drive is also hot swappable, meaning that users can easily connect and use the drive without rebooting the computer. The drive is compatible with Windows(R) operating systems 95, 98, 2000, Me, NT 4.0 Linux (Kernel 2.4.0), and Mac(R) OS 8.5.1 through X. The new Zip 100MB USB Powered drive is expected to be available worldwide in August for a suggested retail price of 99.95. For more information, visit New Zip Here "
For more information about the Iomega Peerless drive system, please visit Peerless. Price and availability The Iomega Peerless drive system can be ordered today by residents of the U.S. through Order Shipments to international regions are expected to begin at the end of May. The drive with interface module retails for 249.95 (U.S. suggested retail price). Individual Peerless disks can be ordered today for 159.95 (10GB) and 199.95 (20GB) (U.S. suggested retail prices). The base station bundled with an interface module and a 20GB disk retails for 399.95 (U.S. suggested retail price). The base station bundled with an interface module and a 10GB disk retails for 359.95. FireWire interface modules are expected to be available within weeks."
We added more IMNX ($17.01) to our "A" Portfolio because they still will sell all the Enbrel they can produce and have a waiting list for Enbrel. IMNX News for IMNX this week: No new news for IMNX.
Corvis Corporation CORV ($3.80) News for CORV: No new news on CORV. CORV
Sycamore Networks (SCMR) ($8.19) News for SCMR: No new news on SCMR. SCMR
Ceragon Networks Ltd. (CRNT $3.21) News for CRNT: No new news for CRNT. CRNT
Capstone Turbine Corp. CPST ($21.19) News for CPST: No new news for CPST. CPST
CORR ($28.98) News from CORR: No new news for CORR. CORR
Three recent additions to the "A" Portfolio are being reported on.
EMBT ($19.87): News for EMBT: No new news for EMBT. EMBT
PALM ($5.23) News for PALM: No new news for PALM. PALM
CMRC ($3.65): News for CMRC: No new news for CMRC. CMRC
HAND ($5.86) Handspring, Inc. News for HAND: No new news for HAND. HAND
CHIR ($51.63) Chiron Corp. is a biotechnology company that is developing products for preventing and treating cancer, infectious diseases and cardiovascular disease. News for CHIR: "BOULDER, Colo. and EMERYVILLE, Calif., June 20 /PRNewswire/ -- Ribozyme Pharmaceuticals Inc. (RPI) (Nasdaq: RZYM) and Chiron Corporation (Nasdaq: CHIR) today announced treatment of the first patient in a Phase II clinical trial evaluating the safety and efficacy of the ribozyme anti- angiogenic drug ANGIOZYME in patients with metastatic colorectal cancer. This study of ANGIOZYME in combination with standard therapy is the second Phase II clinical trial that is investigating the clinical activity of ANGIOZYME in metastatic solid tumors. The first Phase II trial with ANGIOZYME began in February of 2001 in patients with metastatic breast cancer. The first patient was dosed this week by US Oncology. "We are hopeful that results of this trial will reveal that ANGIOZYME may be able to improve upon the clinical results seen with the current standard of care for metastatic colon cancer," said Dr. John Nemunaitis, Medical Director, US Oncology Gene, Cellular, and Special Therapies Program at Mary Crowley Medical Research Center, Dallas, Texas. Approximately 75 patients will be enrolled in this study. Eligible patients will receive ANGIOZYME along with the standard combination chemotherapy regimen of irinotecan, 5-FU and leucovorin. ANGIOZYME will be self-administered by the patients via daily subcutaneous injections. Patients will be eligible to continue ANGIOZYME therapy if either a response or stable disease is present. The principal investigator for this trial is Alan Venook, M.D., of the University of California, San Francisco Comprehensive Cancer Center. Additional sites include The Cleveland Clinic Foundation, Duke University Medical Center, The Sarah Cannon Cancer Center, and several sites of US Oncology, headquartered in Houston, Texas. "The safety of ANGIOZYME has already been examined in a Phase I trial at the Cleveland Clinic. This Phase II trial will examine both the safety and efficacy of ANGIOZYME in this difficult to treat patient population," said Dr. Alan Venook of the University of California, San Francisco Comprehensive Cancer Center. According to the American Cancer Society, there are an estimated 130,200 new cases of colorectal cancer per year in the US. An estimated 56,300 deaths occurred from this disease in 2000. Approximately 1.2 million people suffer from this disease and an estimated 100,000 to 150,000 of these have metastatic colorectal cancer. ANGIOZYME is a ribozyme that targets the high affinity receptor for Vascular Endothelial Growth Factor (VEGF) which is implicated in angiogenesis. ANGIOZYME is designed to decrease VEGF signaling and in that manner, decrease the growth of new blood vessels to tumors, hopefully preventing the spread of cancer. For more information concerning participation in this clinical trial, please visit the RPI web site at rpi or call 1-800-Chiron-8. RPI, located in Boulder, Colorado, is developing ribozymes, the result of Nobel Prize winning science, as a new class of RNA therapeutics designed directly from genomic data for the treatment of cancer and viral diseases. Ribozymes are synthetically engineered to act as "molecular scissors" capable of cleaving target RNA in a highly specific manner, blocking gene expression and preventing production of unwanted proteins." CHIR
MLNM ($32.50) News for MLNM: "CAMBRIDGE, Mass., June 22 /PRNewswire/ -- Millennium Pharmaceuticals, Inc (Nasdaq: MLNM) announced today that its presentation to the First Union Securities Eleventh Annual Nantucket Equity Conference will be webcast and may be accessed at Here Millennium senior management will provide an overview of the Company. The presentation will be delivered at 9:30 a.m. (Eastern Time) on Thursday, June 28th, from the Harbor House in Nantucket, Massachusetts. A replay of the presentation will be available within six hours after the presentation. Millennium, a leading biopharmaceutical company, applies its comprehensive and integrated science and technology platform for the discovery and development of breakthrough therapeutic and predictive medicine products, with a goal of delivering personalized medicine. Through the industrialization of this gene-to-patient platform, Millennium is also striving to accelerate the process of drug discovery and development. Headquartered in Cambridge, Massachusetts, Millennium currently employs more than 1,400 people. MLNM
JDSU ($11.98) News for JDSU: No new news for JDSU. JDSU
MYGN ($58.37) News for MYGN: No new news for MYGN. MYGN
PFE ($42.02) Pfizer Inc. News for PFE: " PHILADELPHIA, June 24 /PRNewswire/ -- More patients with type 2 diabetes who were treated with inhaled insulin (Exubera(TM)) achieved the recommended blood glucose levels than patients who received only insulin injections, according to data presented today at the American Diabetes Association's 61st Annual Scientific Sessions. The six-month study LB-34, which involved 299 patients with type 2 diabetes, compared insulin injections with Exubera(TM) that replaced meal-related injections. Patients in the Phase III study received either injections alone or Exubera(TM) prior to meals plus an insulin injection at bedtime. In the study, more patients taking Exubera(TM) achieved HBA1c levels that were less than 7 percent versus patients taking insulin injections. The HBA1c level reflects blood glucose readings over a period of several months a level below 7 percent is the American Diabetes Association's recommended treatment goal for patients with diabetes. "Despite the proven long-term benefits of tight glycemic control achieved by insulin, there is a reluctance on the part of patients and physicians to treat type 2 diabetes with insulin," said Priscilla A. Hollander, M.D., Ph.D., Medical Director at Baylor University Medical Center in Dallas and lead study investigator. "Our data suggest that Exubera(TM) may lead to earlier introduction of insulin therapy in type 2 diabetes based on patients' acceptance and improved glycemic control." Patients who received Exubera(TM) showed an improvement in blood glucose levels that were equivalent to patients who took insulin injections. Additionally, fewer patients in the Exubera(TM) group experienced hypoglycemia, or abnormally low levels of blood sugar, compared with patients receiving injections. Nearly half of the 16 million Americans with diabetes have blood sugar levels that are not controlled NHANES III. When left uncontrolled, diabetes can lead to kidney failure, blindness, amputations and premature death. In addition, people with diabetes are two to four times more likely to have a heart attack or stroke Juvenile Diabetes Research Foundation. The most common respiratory clinical side effect reported among patients in the study was cough, which was characterized as mild to moderate in nature. Pulmonary function tests showed no significant differences between patients receiving Exubera(TM) versus those who received injections. Exubera(TM) is being developed for patients with type 1 and type 2 diabetes through a collaboration between Pfizer Inc and Aventis Pharma. The two companies have entered into a global agreement to co-develop, co-promote (where permitted by local law) and co-manufacture inhaled insulin. Pfizer is also in collaboration with Inhale Therapeutic Systems, developers of the inhalation device and formulation process." PFE
New stocks for this newsletter and to our "A" Portfolio.
EXTR ($24.27) Extreme Networks provides switching solutions that meet the needs of enterprise local area networks, via utilization of ASIC semiconductors throughout the product line. News for EXTR: No new news for EXTR. EXTR
PBSC ($8.05) Packard BioScience is a developer, manufacturer and marketer of instruments and related consumables and services for use in the life sciences research and nuclear industries. News for PBSC: No new news for PBSC. PBSC
EXDS ($2.13) was added to our "A" Portfolio at $8.00. EXDS is a provider of Internet system and network management solutions. EXDS offers server hosting, Internet connectivity, collaborative systems management and Internet technology services. News for EXDS: No new news for EXDS.EXDS
RBAK ($9.510 was added at $10.55 on June 18, 2001. Here is some information on RBAK: Redback Networks is a provider of advanced networkingsystems that enable carriers, cable operators and service providers to rapidly deploy high-speed broadband access to the Internet and corporate networks. News for RBAK: No new news for RBAK. RBAK
New additions to our "A" Portfolio made on June 18, 2001: IOM @ $2.10; JDSU @ $11.00; PALM @ $4.56; HAND @ $5.53; GLW @ $13.68; CPST @ $20.70; RBAK @ $10.55; EXDS @ $3.85; CORV @ $3.81; and SCMR @ $7.87.
With the Market being so volatile, a trader should have some close mental stops in the stocks they buy. We suggest a mental stop of 20% is used where appropriate.Income and Bonds
We recommend buying utilities based in Florida and not any utilities based in California. The reason is California based utilities do not produce enough of their own power and have to go onto the open market to buy power during peak usage. California utilities are having trouble and two of them Edison Intl. (EIX) and P G & E Corp. (PCG) are having problems so stay away from them for now. PCG has declared bankruptcy last week and Edison Intl. (EIX) has said they will not declare bankruptcy for now. We would stay away from any power generators that supply power to any California utilities at this time. For a person needing some income be sure to look into electric utilities for some bargain buying opportunities to take advantage of the high dividend paying utilities. We would buy 5-year and 10-year treasuries for income and some appreciation if interest rates are lowered this year. We recommend 3-6 months Treasuries because they are currently yielding 4.0%. CEI ($24.83) yield has gone down to 8.85% but it is still a buy for its yield and our target is $35. We also like these two reits: CRE ($28.92) yielding 6.43% CarrAmerica Realty is a REIT that focuses primarily on the acquisition, development, ownership and operation of office properties in suburban growth markets in the U.S. Forthe FY ended 12/31/00, revenues rose 8% to $558M. Net income from continuing operation fell 3% to $147.2M. Revenues reflect the development of properties being placed in service and higher occupany rate for store properties. Earnings were offset by a lower gain on the sale of assets. CRE and SPG ($27.75) yielding 7.63% Simon Property Group, Inc. is a self-administered and self-managed REIT company, primarily engaged in the expansion & development of real estate properties, primarily malls and shopping centers. For the fiscal year ended 12/31/00, revenues rose 7% to $2.02B. Net income before extra item & acct. change, applic. to Common and limited partners rose 14% to $347.4M. Revenues reflect the CPI merger. Net income reflects gains vs. losses on RE sales. SPG
We have another energy stock we like that has some risk but not as much risk as some of the other energy stocks out in the market. The stock is Entergy (ETR). We added ETR ($38.90) to the "A" Portfolio at $38.50 on April 16th, 2001. News on ETR: No new news for ETR. ETR
Stocks for 2001
The new stocks we have added to our charts for 2001 are: INSP; IMNX; ICOS; TQNT; TGEN; SBUX; RSTA; CRXA; COST; WM; ISLD; MCOM; CHKP; EMLX; ITWO; MANU; JNPR; MUSE; VRTS; QLGC; VRTY; ACRT; AREM; CHCS; INRS; PWER; PDII; SNWL; CHEZ; KO; CORV; GPS; GSPN; MDT; MRCY; AMCC; VTSS; XLNX; BKE; MYGN; CHIR; APC; DVN; JNY; MCLD; NBR; PTEN; QQQ; and TXN. We dropped the following stocks: T; EWEB; ROWE; SGAI; PCOR; PCNTF; ICY; AND LU. You will notice there we be more sections in the charts section of the website. We still will have sections called 12 month, Like, and Tracking. With new sections for Beaten up stocks from 2000, an ADV section for stocks new to our Newsletter, and a section called Dogs of the Dow. Dogs of the Dow are five stocks chosen from the Dow Jones Average of 30 stocks that has shown to beat the market over the past few years.
Some the company's reports written about Stocks 2001 in the newsletter are here Stock Picks 2001
With the Market being so volatile, a trader should have some close mental stops in the stocks they buy. We suggest a mental stop of 30% is used where appropriate.
Readers will notice all our stocks we follow are on a separate page and we will list prices to purchase stocks at and a target price that we feel the stocks have of reaching in 12 months.